BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...

On Nov. 18, the heart failure and transplantation team at Emory University Hospital (EUH) made history, performing the first-ever surgical implantation in the United States of a brand-new type of ...

Just over a month after it was approved in the UK, AstraZeneca and Ionis' Wainzua has been recommended for NHS use in the ...

BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.

Alnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...

California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...